Ritonavir (Norvir) ( DrugBank: Ritonavir )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 265 | Lipodystrophy | 1 |
265. Lipodystrophy
Clinical trials : 112 / Drugs : 155 - (DrugBank : 55) / Drug target genes : 25 - Drug target pathways : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00426296 (ClinicalTrials.gov) | August 2006 | 23/1/2007 | SHARE: Simple HAART With Abacavir, Reyataz, and Epivir | An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks | HIV Infections;Lipodystrophy | Drug: atazanavir (Reyataz);Drug: ritonavir (Norvir) | Clinical Alliance for Research & Education - Infectious Diseases, LLC. | GlaxoSmithKline | Recruiting | 18 Years | N/A | Both | Phase 4 | United States |